The autologous stem cell and non-stem cell based therapies market involves medical procedures that use an individual’s own stem cells or other types of cells to repair damaged tissue. Autologous stem cell therapy involves collecting stem cells from a patient’s own bone marrow or fat tissue and then infusing them back into the patient’s body with the goal of regenerating damaged or diseased cells and tissues. Non-stem cell based therapies make use of other types of cells such as keratinocytes, tenocytes, chondrocytes, and fibroblasts to repair skin, tendons, cartilage, and other connective tissues respectively.
The Global autologous stem cell and non-stem cell based therapies market is estimated to be valued at US$ 98.8 Bn in 2024 and is expected to exhibit a CAGR of 4.3% over the forecast period 2023 to 2030.
Key Takeaways
Key players operating in the autologous stem cell and non-stem cell based therapies are Caladrius Biosciences, Vericel Corporation, Fibrocell Science, Inc., Genzyme Corporation, BrainStorm Cell Therapeutics, Regeneus Ltd., and Dendreon Corporation. These players are focusing on developing advanced treatment procedures and launching novel therapeutics in the market.
The autologous stem cell and non-stem cell based therapies market provides significant opportunities for treatment of various chronic diseases and severe injuries. Ongoing research in stem cell biology has increased application of these therapies in regenerative medicine. Further, increasing investment by private organizations and favorable regulatory environment are fueling market growth.
Globally, the autologous stem cell and non-stem cell based therapies market is expanding rapidly with presence across major regions including North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. Emerging nations like China, India, Brazil and South Africa are projected to become major markets owing to rising healthcare investment and demand for advanced therapeutic options.
Market drivers
Increasing prevalence of chronic medical conditions worldwide like Parkinson’s disease, diabetes, cardiovascular diseases is a major factor driving the autologous stem cell and non-stem cell based therapies market. These therapies provide promising treatment options for various disabling and life-threatening diseases. Further, growing geriatric population which is more prone to orthopedic conditions and neurodegenerative disorders is also supporting market growth.
PEST Analysis
Political: Regulations and compliances for stem cell therapies are complex due to ethical debates. However, countries are supporting research to enable advancements.
Economic: Cost of therapy development is high due to stringent requirements. Spending on healthcare is increasing globally supporting market growth.
Social: Aging population and increasing incidence of diseases like cancer are key factors driving demand. Public awareness about new treatment options is also improving.
Technological: Research is ongoing to overcome challenges in stem cell processing, storage and targeting. Combination therapies are being explored to improve clinical outcomes.
The North American region accounted for the largest share of the global autologous stem cell and non-stem cell based therapies market in terms of value in 2023. This can be attributed to the growing geriatric population, increasing incidence of chronic diseases, rising healthcare expenditure, and rapid adoption of advanced technologies in the region. The Asia Pacific region is expected to witness the fastest growth during the forecast period owing to growing medical tourism, improving healthcare infrastructure, rising disposable incomes, and increasing awareness about new treatment alternatives.